{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T22:24:30Z","timestamp":1782512670004,"version":"3.54.5"},"reference-count":113,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2013,7,17]],"date-time":"2013-07-17T00:00:00Z","timestamp":1374019200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1007\/s11239-013-0967-z","type":"journal-article","created":{"date-parts":[[2013,7,16]],"date-time":"2013-07-16T13:18:03Z","timestamp":1373980683000},"page":"217-233","source":"Crossref","is-referenced-by-count":55,"title":["The pharmacology of novel oral anticoagulants"],"prefix":"10.1007","volume":"37","author":[{"given":"Tracy A.","family":"DeWald","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard C.","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,7,17]]},"reference":[{"issue":"4","key":"967_CR1","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/j.1365-2125.2011.03916.x","volume":"72","author":"CJ Lee","year":"2011","unstructured":"Lee CJ, Ansell JE (2011) Direct thrombin inhibitors. Br J Clin Pharmacol 72(4):581\u2013592","journal-title":"Br J Clin Pharmacol"},{"issue":"Suppl 2","key":"967_CR2","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/S0049-3848(10)70147-X","volume":"127","author":"JI Weitz","year":"2011","unstructured":"Weitz JI (2011) Factor Xa and thrombin as targets for new oral anticoagulants. Thromb Res 127(Suppl 2):S5\u2013S12","journal-title":"Thromb Res"},{"issue":"11","key":"967_CR3","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"CB Granger","year":"2011","unstructured":"Granger CB et al (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365(11):981\u2013992","journal-title":"N Engl J Med"},{"issue":"12","key":"967_CR4","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"SJ Connolly","year":"2009","unstructured":"Connolly SJ et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. [Erratum appears in N Engl J Med. 2010 Nov 4;363(19):1877]. N Engl J Med 361(12):1139\u20131151","journal-title":"N Engl J Med"},{"issue":"10","key":"967_CR5","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"MR Patel","year":"2011","unstructured":"Patel MR et al (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365(10):883\u2013891","journal-title":"N Engl J Med"},{"issue":"9","key":"967_CR6","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1021\/jm0109513","volume":"45","author":"NH Hauel","year":"2002","unstructured":"Hauel NH et al (2002) Structure-based design of novel potent nonpeptide thrombin inhibitors. J Med Chem 45(9):1757\u20131766","journal-title":"J Med Chem"},{"issue":"1","key":"967_CR7","first-page":"155","volume":"98","author":"W Wienen","year":"2007","unstructured":"Wienen W et al (2007) In-vitro profile and ex vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate. Thromb Haemost 98(1):155\u2013162","journal-title":"Thromb Haemost"},{"issue":"1","key":"967_CR8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/0003088-200948010-00001","volume":"48","author":"BI Eriksson","year":"2009","unstructured":"Eriksson BI, Quinlan DJ, Weitz JI (2009) Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development. Clin Pharmacokinet 48(1):1\u201322","journal-title":"Clin Pharmacokinet"},{"issue":"3 Suppl","key":"967_CR9","doi-asserted-by":"crossref","first-page":"4S","DOI":"10.1378\/chest.124.3_suppl.4S","volume":"124","author":"KG Mann","year":"2003","unstructured":"Mann KG (2003) Thrombin formation. Chest 124(3 Suppl):4S\u201310S","journal-title":"Chest"},{"issue":"5","key":"967_CR10","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2165\/00129784-200505050-00001","volume":"5","author":"JH Alexander","year":"2005","unstructured":"Alexander JH, Singh KP (2005) Inhibition of Factor Xa: a potential target for the development of new anticoagulants. Am J Cardiovas Drugs 5(5):279\u2013290","journal-title":"Am J Cardiovas Drugs"},{"key":"967_CR11","volume-title":"Clinical pharmacokinetics","author":"M Rowland","year":"1995","unstructured":"Rowland M, Tozer TN (1995) Concepts and applications. In: Balado D (ed) Clinical pharmacokinetics, vol 3rd edn. Williams and Wilkins, Philadelphia"},{"issue":"3","key":"967_CR12","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrd3028","volume":"9","author":"International Transporter Consortium","year":"2010","unstructured":"International Transporter Consortium et al (2010) Membrane transporters in drug development. Nat Rev Drug Discov 9(3):215\u2013236","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"967_CR13","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.apsb.2012.10.004","volume":"2","author":"D Zhang","year":"2012","unstructured":"Zhang D, Luo G, Ding X, Lu C (2012) Preclinical experimental models of drug metabolism and disposition in drug discovery and development. Acta Pharmaceutica Sinica B 2(6):549\u2013561","journal-title":"Acta Pharmaceutica Sinica B"},{"key":"967_CR14","author":"M Estudante","year":"2012","unstructured":"Estudante M, Morais JG, Soveral G, Benet LZ (2012) Intestinal drug transporters: an overview. Adv Drug Deliv Rev. doi: 10.1016\/j.addr.2012.09.042","journal-title":"Adv Drug Deliv Rev"},{"issue":"10","key":"967_CR15","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1093\/hmg\/5.10.1649","volume":"5","author":"R Allikmets","year":"1996","unstructured":"Allikmets R et al (1996) Characterization of the human ABC superfamily: isolation and mapping of 21 new genes using the expressed sequence tags database. Hum Mol Genet 5(10):1649\u20131655","journal-title":"Hum Mol Genet"},{"issue":"4 Pt 2","key":"967_CR16","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/0091-6749(86)90047-3","volume":"78","author":"AL Golub","year":"1986","unstructured":"Golub AL et al (1986) Physiologic considerations in drug absorption from the gastrointestinal tract. J Allergy Clin Immunol 78(4 Pt 2):689\u2013694","journal-title":"J Allergy Clin Immunol"},{"key":"967_CR17","volume-title":"3rd edn","author":"ME Winter","year":"1994","unstructured":"Winter ME (1994) Basic Clinical Pharmacokinetics. In: Koda-Kimble MY, Young LY (eds) 3rd edn. Applied Therapeutics, Vancouver"},{"issue":"8\u20139","key":"967_CR18","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1080\/00498250110060969","volume":"31","author":"A Ayrton","year":"2001","unstructured":"Ayrton A, Morgan P (2001) Role of transport proteins in drug absorption, distribution and excretion. Xenobiotica 31(8\u20139):469\u2013497","journal-title":"Xenobiotica"},{"issue":"2","key":"967_CR19","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1208\/s12248-009-9102-7","volume":"11","author":"A Grover","year":"2009","unstructured":"Grover A, Benet LZ (2009) Effects of drug transporters on volume of distribution. AAPS Journal 11(2):250\u2013261","journal-title":"AAPS Journal"},{"issue":"1","key":"967_CR20","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1365-2125.2005.02389.x","volume":"60","author":"M Thorn","year":"2005","unstructured":"Thorn M et al (2005) Cytochromes P450 and MDR1 mRNA expression along the human gastrointestinal tract. Br J Clin Pharmacol 60(1):54\u201360","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"967_CR21","doi-asserted-by":"crossref","first-page":"106","DOI":"10.2133\/dmpk.DMPK-11-RV-099","volume":"27","author":"T Nakanishi","year":"2012","unstructured":"Nakanishi T, Tamai I (2012) Genetic polymorphisms of OATP transporters and their impact on intestinal absorption and hepatic disposition of drugs. Drug Metab Pharmacokinet 27(1):106\u2013121","journal-title":"Drug Metab Pharmacokinet"},{"issue":"3","key":"967_CR22","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1006\/scbi.1997.0068","volume":"8","author":"AH Schinkel","year":"1997","unstructured":"Schinkel AH (1997) The physiological function of drug-transporting P-glycoproteins. Semin Cancer Biol 8(3):161\u2013170","journal-title":"Semin Cancer Biol"},{"issue":"21","key":"967_CR23","doi-asserted-by":"crossref","first-page":"7735","DOI":"10.1073\/pnas.84.21.7735","volume":"84","author":"F Thiebaut","year":"1987","unstructured":"Thiebaut F et al (1987) Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 84(21):7735\u20137738","journal-title":"Proc Natl Acad Sci USA"},{"issue":"11","key":"967_CR24","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1111\/j.1440-1681.2007.04691.x","volume":"34","author":"R Canaparo","year":"2007","unstructured":"Canaparo R et al (2007) Expression of CYP3A isoforms and P-glycoprotein in human stomach, jejunum and ileum. Clin Exp Pharmacol Physiol 34(11):1138\u20131144","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"10","key":"967_CR25","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1111\/j.2042-7158.1996.tb05904.x","volume":"48","author":"T Terao","year":"1996","unstructured":"Terao T et al (1996) Active secretion of drugs from the small intestinal epithelium in rats by P-glycoprotein functioning as an absorption barrier. J Pharm Pharmacol 48(10):1083\u20131089","journal-title":"J Pharm Pharmacol"},{"issue":"9","key":"967_CR26","doi-asserted-by":"crossref","first-page":"4001","DOI":"10.1073\/pnas.93.9.4001","volume":"93","author":"EG Schuetz","year":"1996","unstructured":"Schuetz EG et al (1996) P-glycoprotein: a major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans. Proc Natl Acad Sci USA 93(9):4001\u20134005","journal-title":"Proc Natl Acad Sci USA"},{"key":"967_CR27","first-page":"101","volume":"13","author":"JA Silverman","year":"1995","unstructured":"Silverman JA, Thorgeirsson SS (1995) Regulation and function of the multidrug resistance genes in liver. Prog Liver Dis 13:101\u2013123","journal-title":"Prog Liver Dis"},{"issue":"3","key":"967_CR28","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/mc.2940130302","volume":"13","author":"VJ Wacher","year":"1995","unstructured":"Wacher VJ, Wu CY, Benet LZ (1995) Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 13(3):129\u2013134","journal-title":"Mol Carcinog"},{"issue":"3","key":"967_CR29","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2165\/00003088-200140030-00002","volume":"40","author":"Y Zhang","year":"2001","unstructured":"Zhang Y, Benet LZ (2001) The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein. Clin Pharmacokinet 40(3):159\u2013168","journal-title":"Clin Pharmacokinet"},{"issue":"12","key":"967_CR30","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1592\/phco.31.12.1175","volume":"31","author":"AK Wittkowsky","year":"2011","unstructured":"Wittkowsky AK (2011) Novel oral anticoagulants and their role in clinical practice. Pharmacotherapy 31(12):1175\u20131191","journal-title":"Pharmacotherapy"},{"key":"967_CR31","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/978-3-642-14541-4_6","volume":"201","author":"I Cascorbi","year":"2011","unstructured":"Cascorbi I (2011) P-glycoprotein: tissue distribution, substrates, and functional consequences of genetic variations. Exp Pharmacol 201:261\u2013283","journal-title":"Exp Pharmacol"},{"issue":"3","key":"967_CR32","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.clpt.2003.10.008","volume":"75","author":"O Richter von","year":"2004","unstructured":"von Richter O et al (2004) Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: a comparative analysis in paired tissue specimens. Clin Pharmacol Ther 75(3):172\u2013183","journal-title":"Clin Pharmacol Ther"},{"issue":"1\u20132","key":"967_CR33","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0168-3659(99)00034-6","volume":"62","author":"LZ Benet","year":"1999","unstructured":"Benet LZ et al (1999) Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery. J Controlled Release 62(1\u20132):25\u201331","journal-title":"J Controlled Release"},{"issue":"3","key":"967_CR34","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.taap.2004.10.012","volume":"204","author":"EM Leslie","year":"2005","unstructured":"Leslie EM, Deeley RG, Cole SPC (2005) Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol 204(3):216\u2013237","journal-title":"Toxicol Appl Pharmacol"},{"issue":"Suppl 2","key":"967_CR35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1365-2362.33.s2.5.x","volume":"33","author":"RB Kim","year":"2003","unstructured":"Kim RB (2003) Organic anion-transporting polypeptide (OATP) transporter family and drug disposition. Eur J Clin Invest 33(Suppl 2):1\u20135","journal-title":"Eur J Clin Invest"},{"issue":"2","key":"967_CR36","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1006\/bbrc.1998.9298","volume":"250","author":"PV Balimane","year":"1998","unstructured":"Balimane PV et al (1998) Direct evidence for peptide transporter (PepT1)-mediated uptake of a nonpeptide prodrug, valacyclovir. Biochem Biophys Res Commun 250(2):246\u2013251","journal-title":"Biochem Biophys Res Commun"},{"issue":"7","key":"967_CR37","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1023\/A:1016086003070","volume":"13","author":"A Tsuji","year":"1996","unstructured":"Tsuji A, Tamai I (1996) Carrier-mediated intestinal transport of drugs. Pharm Res 13(7):963\u2013977","journal-title":"Pharm Res"},{"issue":"3","key":"967_CR38","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1476-5381.2009.00430.x","volume":"158","author":"A Kalliokoski","year":"2009","unstructured":"Kalliokoski A, Niemi M (2009) Impact of OATP transporters on pharmacokinetics. Br J Pharmacol 158(3):693\u2013705","journal-title":"Br J Pharmacol"},{"issue":"3","key":"967_CR39","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.pharmthera.2007.09.004","volume":"116","author":"M Ingelman-Sundberg","year":"2007","unstructured":"Ingelman-Sundberg M et al (2007) Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 116(3):496\u2013526","journal-title":"Pharmacol Ther"},{"issue":"3","key":"967_CR40","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S0009-9236(97)90027-8","volume":"62","author":"KS Lown","year":"1997","unstructured":"Lown KS et al (1997) Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther 62(3):248\u2013260","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"967_CR41","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1365-2125.2007.02899.x","volume":"64","author":"J Stangier","year":"2007","unstructured":"Stangier J et al (2007) The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 64(3):292\u2013303","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"967_CR42","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1124\/dmd.107.019083","volume":"36","author":"S Blech","year":"2008","unstructured":"Blech S et al (2008) The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 36(2):386\u2013399","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"967_CR43","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1177\/0091270005274550","volume":"45","author":"J Stangier","year":"2005","unstructured":"Stangier J et al (2005) Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol 45(5):555\u2013563","journal-title":"J Clin Pharmacol"},{"key":"967_CR44","volume-title":"Pradaxa (dabigatran) prescribing information","author":"Boehringer Ingelheim Pharmaceuticals Inc.","year":"2012","unstructured":"Boehringer Ingelheim Pharmaceuticals Inc. (2012) Pradaxa (dabigatran) prescribing information. Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield"},{"issue":"5","key":"967_CR45","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2165\/00003088-200847050-00001","volume":"47","author":"J Stangier","year":"2008","unstructured":"Stangier J (2008) Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet 47(5):285\u2013295","journal-title":"Clin Pharmacokinet"},{"key":"967_CR46","unstructured":"Kishimoto W, Ishiguro N, Saito A, et al. (2010) Characterization of drug transporters involved in the disposition of dabigatran etexilate and its active form, dabigatran. In: Abstract 9th International Meeting of the International Society for the Study of Xenobiotics (ISSX). Istanbul"},{"issue":"3","key":"967_CR47","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/0006-291X(91)91647-U","volume":"175","author":"P Artursson","year":"1991","unstructured":"Artursson P, Karlsson J (1991) Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem Biophys Res Commun 175(3):880\u2013885","journal-title":"Biochem Biophys Res Commun"},{"issue":"11","key":"967_CR48","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1111\/j.1538-7836.2011.04498.x","volume":"9","author":"KH Liesenfeld","year":"2011","unstructured":"Liesenfeld KH et al (2011) Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial. J Thromb Haemost 9(11):2168\u20132175","journal-title":"J Thromb Haemost"},{"key":"967_CR49","volume-title":"Xarelto (rivaroxaban) prescribing information","author":"Janssen Pharmaceuticals Inc.","year":"2011","unstructured":"Janssen Pharmaceuticals Inc. (2011) Xarelto (rivaroxaban) prescribing information. Janssen Pharmaceuticals Inc., Titusville"},{"issue":"5","key":"967_CR50","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1177\/0091270006286904","volume":"46","author":"D Kubitza","year":"2006","unstructured":"Kubitza D et al (2006) Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects. J Clin Pharmacol 46(5):549\u2013558","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"967_CR51","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2165\/00003088-199937030-00003","volume":"37","author":"BN Singh","year":"1999","unstructured":"Singh BN (1999) Effects of food on clinical pharmacokinetics. Clin Pharmacokinet 37(3):213\u2013255","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"967_CR52","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1124\/jpet.111.180240","volume":"338","author":"MJ Gnoth","year":"2011","unstructured":"Gnoth MJ, Buetehorn U, Muenster U, Schwarz T, Sandmann S (2011) In vitro and in vivo p-glycoprotein transport characteristics of rivaroxaban. J Pharmacol Exp Ther 338(1):372\u2013380","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"967_CR53","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2174\/1389200043489199","volume":"5","author":"A Haimeur","year":"2004","unstructured":"Haimeur A et al (2004) The MRP-related and BCRP\/ABCG2 multidrug resistance proteins: biology, substrate specificity and regulation. Curr Drug Metab 5(1):21\u201353","journal-title":"Curr Drug Metab"},{"issue":"1","key":"967_CR54","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0169-409X(02)00175-8","volume":"55","author":"AH Dantzig","year":"2003","unstructured":"Dantzig AH, de Alwis DP, Burgess M (2003) Considerations in the design and development of transport inhibitors as adjuncts to drug therapy. Adv Drug Deliv Rev 55(1):133\u2013150","journal-title":"Adv Drug Deliv Rev"},{"issue":"3","key":"967_CR55","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s11130-004-0049-7","volume":"59","author":"LH Yao","year":"2004","unstructured":"Yao LH et al (2004) Flavonoids in food and their health benefits. Plant Foods Hum Nutr 59(3):113\u2013122","journal-title":"Plant Foods Hum Nutr"},{"issue":"5","key":"967_CR56","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1124\/mol.65.5.1208","volume":"65","author":"S Zhang","year":"2004","unstructured":"Zhang S, Yang X, Morris ME (2004) Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport. Mol Pharmacol 65(5):1208\u20131216","journal-title":"Mol Pharmacol"},{"issue":"1","key":"967_CR57","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1124\/dmd.108.023143","volume":"37","author":"N Raghavan","year":"2009","unstructured":"Raghavan N et al (2009) Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos 37(1):74\u201381","journal-title":"Drug Metab Dispos"},{"issue":"12","key":"967_CR58","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1111\/j.1538-7836.2007.02764.x","volume":"5","author":"MR Lassen","year":"2007","unstructured":"Lassen MR et al (2007) The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J Thromb Haemost 5(12):2368\u20132375","journal-title":"J Thromb Haemost"},{"issue":"6","key":"967_CR59","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1056\/NEJMoa0810773","volume":"361","author":"MR Lassen","year":"2009","unstructured":"Lassen MR et al (2009) Apixaban or enoxaparin for thromboprophylaxis after knee replacement. [Erratum appears in N Engl J Med. 2009 Oct 29;361(18):1814]. N Engl J Med 361(6):594\u2013604","journal-title":"N Engl J Med"},{"issue":"8","key":"967_CR60","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1111\/j.1538-7836.2008.03054.x","volume":"6","author":"Botticelli Investigators","year":"2008","unstructured":"Botticelli Investigators et al (2008) Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. J Thromb Haemost 6(8):1313\u20131318","journal-title":"J Thromb Haemost"},{"key":"967_CR61","unstructured":"Frost CE (2007) Apixaban, an oral direct factor Xa inhibitor: multiple-dose dafety, pharmacokinetics, and pharmacodynamics in healthy subjects. XXIst ISTH Congress, 5 (Supplement 2):P-M-664"},{"issue":"9","key":"967_CR62","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1056\/NEJMoa1007432","volume":"364","author":"SJ Connolly","year":"2011","unstructured":"Connolly SJ et al (2011) Apixaban in patients with atrial fibrillation. N Engl J Med 364(9):806\u2013817","journal-title":"N Engl J Med"},{"key":"967_CR63","unstructured":"Bristol-Myers Squibb Pharmaceuticals (2012) Eliquis (apixaban) product information. Bristol-Myers Squibb Pharmaceuticals, Princeton"},{"key":"967_CR64","unstructured":"Bristol-Myers Squibb Pharmaceuticals (2011) Eliquis (apixaban) product information. Bristol-Myers Squibb Pharmaceuticals, Melbourne"},{"key":"967_CR65","doi-asserted-by":"crossref","unstructured":"He K, He B, Grace JE, et al. (2006) Preclinical pharmacokinetic and metabolism of apixaban, a potent and selective factor Xa inhibitor. 2006 Annual meeting abstracts. Blood 108(11) abstract 910","DOI":"10.1182\/blood.V108.11.910.910"},{"issue":"7","key":"967_CR66","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1177\/0091270009351883","volume":"50","author":"K Ogata","year":"2010","unstructured":"Ogata K et al (2010) Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol 50(7):743\u2013753","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"967_CR67","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1177\/0091270010370974","volume":"51","author":"J Mendell","year":"2011","unstructured":"Mendell J et al (2011) Effects of food on the pharmacokinetics of edoxaban, an oral direct factor Xa inhibitor, in healthy volunteers. J Clin Pharmacol 51(5):687\u2013694","journal-title":"J Clin Pharmacol"},{"key":"967_CR68","unstructured":"Matsushima N, Lee F, Sato T, Weiss D, Mendell J (2011) Absolute bioavailability of edoxaban in healthy subjects. 2011 AAPS Annual Meeting and Exposition. Poster number T2362, Washington, DC"},{"issue":"S2","key":"967_CR69","first-page":"W4308","volume":"12","author":"H Masumoto","year":"2010","unstructured":"Masumoto H, Yoshigae Y, Watanabe K et al (2010) In vitro metabolism of edoxaban and the enzymes involved in the oxidative metabolism of edoxaban (abstract). AAPS J 12(S2):W4308","journal-title":"AAPS J"},{"issue":"12","key":"967_CR70","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.2165\/11595540-000000000-00000","volume":"71","author":"AJ Camm","year":"2011","unstructured":"Camm AJ, Bounameaux H (2011) Edoxaban: a new oral direct factor Xa inhibitor. Drugs 71(12):1503\u20131526","journal-title":"Drugs"},{"issue":"5","key":"967_CR71","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1160\/TH11-08-0566","volume":"107","author":"DE Salazar","year":"2012","unstructured":"Salazar DE et al (2012) Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation. Thromb Haemost 107(5):925\u2013936","journal-title":"Thromb Haemost"},{"key":"967_CR72","unstructured":"Mikkaichi T, Yoshigae Y, Masumoto H, et al. (2012) Edoxaban transport via p-glycoprotein is a key factor for the drug disposition. In: Abstract 18th North American International Society for the Study of Xenobiotics. Dallas"},{"issue":"4","key":"967_CR73","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1081\/DMR-120026871","volume":"35","author":"JH Lin","year":"2003","unstructured":"Lin JH, Yamazaki M (2003) Clinical relevance of P-glycoprotein in drug therapy. Drug Metab Rev 35(4):417\u2013454","journal-title":"Drug Metab Rev"},{"key":"967_CR74","volume-title":"Applied biopharmaceutics and pharmacokinetics","author":"LY Shargel","year":"1993","unstructured":"Shargel LY, Yu ABC (1993) Applied biopharmaceutics and pharmacokinetics, 3rd edn. Appleton and Lange, Norwalk","edition":"3"},{"issue":"Suppl 1","key":"967_CR75","doi-asserted-by":"crossref","first-page":"9S","DOI":"10.1177\/1076029609343004","volume":"15","author":"J Stangier","year":"2009","unstructured":"Stangier J, Clemens A (2009) Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor. Clin Appl Thromb Hemost 15(Suppl 1):9S\u201316S","journal-title":"Clin Appl Thromb Hemost"},{"issue":"4","key":"967_CR76","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1007\/s11239-011-0551-3","volume":"31","author":"PC Wong","year":"2011","unstructured":"Wong PC, Pinto DJP, Zhang D (2011) Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor. J Thromb Thrombolysis 31(4):478\u2013492","journal-title":"J Thromb Thrombolysis"},{"issue":"1","key":"967_CR77","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1093\/oxfordjournals.annonc.a057676","volume":"1","author":"P Valk van der","year":"1990","unstructured":"van der Valk P et al (1990) Distribution of multi-drug resistance-associated P-glycoprotein in normal and neoplastic human tissues. Analysis with 3 monoclonal antibodies recognizing different epitopes of the P-glycoprotein molecule. Ann Oncol 1(1):56\u201364","journal-title":"Ann Oncol"},{"issue":"8","key":"967_CR78","first-page":"3458","volume":"61","author":"M Maliepaard","year":"2001","unstructured":"Maliepaard M et al (2001) Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res 61(8):3458\u20133464","journal-title":"Cancer Res"},{"issue":"5","key":"967_CR79","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1023\/B:PHAM.0000026420.79421.8f","volume":"21","author":"P Chandra","year":"2004","unstructured":"Chandra P, Brouwer KLR (2004) The complexities of hepatic drug transport: current knowledge and emerging concepts. Pharm Res 21(5):719\u2013735","journal-title":"Pharm Res"},{"key":"967_CR80","first-page":"33","volume-title":"Pharmacotherapy: a pathophysiologic approach","author":"L Bauer","year":"2002","unstructured":"Bauer L (2002) Clinical pharmacokinetics and pharmacodynamics. In: DiPiro J (ed) Pharmacotherapy: a pathophysiologic approach. McGraw-Hill, New York, pp 33\u201353"},{"issue":"3","key":"967_CR81","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.bbagen.2006.09.019","volume":"1770","author":"J Kirchheiner","year":"2007","unstructured":"Kirchheiner J, Seeringer A (2007) Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes. Biochim Biophys Acta 1770(3):489\u2013494","journal-title":"Biochim Biophys Acta"},{"issue":"4","key":"967_CR82","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.tips.2004.02.007","volume":"25","author":"M Ingelman-Sundberg","year":"2004","unstructured":"Ingelman-Sundberg M (2004) Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. Trends Pharmacol Sci 25(4):193\u2013200","journal-title":"Trends Pharmacol Sci"},{"key":"967_CR83","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1146\/annurev.med.56.082103.104724","volume":"57","author":"M Eichelbaum","year":"2006","unstructured":"Eichelbaum M, Ingelman-Sundberg M, Evans WE (2006) Pharmacogenomics and individualized drug therapy. Annu Rev Med 57:119\u2013137","journal-title":"Annu Rev Med"},{"issue":"3","key":"967_CR84","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.clpt.2005.05.011","volume":"78","author":"RH Ho","year":"2005","unstructured":"Ho RH, Kim RB (2005) Transporters and drug therapy: implications for drug disposition and disease. Clin Pharmacol Ther 78(3):260\u2013277","journal-title":"Clin Pharmacol Ther"},{"key":"967_CR85","first-page":"41","volume-title":"Goodman & Gilman\u2019s the pharmacological basis of therapeutics","author":"K Giacomini","year":"2006","unstructured":"Giacomini K, Sugiyama Y (2006) Membrane transporters and drug response. In: Brunton L, Lazo JS, Parker KL (eds) Goodman & Gilman\u2019s the pharmacological basis of therapeutics. McGraw-Hill, New York, pp 41\u201370"},{"issue":"5","key":"967_CR86","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1517\/17425255.4.5.545","volume":"4","author":"AT Nies","year":"2008","unstructured":"Nies AT, Schwab M, Keppler D (2008) Interplay of conjugating enzymes with OATP uptake transporters and ABCC\/MRP efflux pumps in the elimination of drugs. Expert Opin Drug Metab Toxicol 4(5):545\u2013568","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"967_CR87","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1053\/bega.2002.0340","volume":"16","author":"RP Oude Elferink","year":"2002","unstructured":"Oude Elferink RP (2002) Understanding and controlling hepatobiliary function. Best Pract Res Clin Gastroenterol 16:1025\u20131034","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"6","key":"967_CR88","doi-asserted-by":"crossref","first-page":"529","DOI":"10.2165\/00002018-200528060-00005","volume":"28","author":"F Delco","year":"2005","unstructured":"Delco F et al (2005) Dose adjustment in patients with liver disease. Drug Saf 28(6):529\u2013545","journal-title":"Drug Saf"},{"issue":"1","key":"967_CR89","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1177\/00912700022008649","volume":"40","author":"SI Sokol","year":"2000","unstructured":"Sokol SI et al (2000) Cardiovascular drug therapy in patients with hepatic diseases and patients with congestive heart failure. J Clin Pharmacol 40(1):11\u201330","journal-title":"J Clin Pharmacol"},{"issue":"12","key":"967_CR90","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s00228-008-0553-z","volume":"64","author":"RK Verbeeck","year":"2008","unstructured":"Verbeeck RK (2008) Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol 64(12):1147\u20131161","journal-title":"Eur J Clin Pharmacol"},{"issue":"5","key":"967_CR91","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/path.1379","volume":"200","author":"JE Ros","year":"2003","unstructured":"Ros JE et al (2003) High expression of MDR1, MRP1, and MRP3 in the hepatic progenitor cell compartment and hepatocytes in severe human liver disease. J Pathol 200(5):553\u2013560","journal-title":"J Pathol"},{"issue":"Supplement 2","key":"967_CR92","first-page":"P-M-635","volume":"5","author":"A Halabi","year":"2007","unstructured":"Halabi A, Kubitza D, Zuehlsdorf M, Becka M, Mueck W, Maatouk H (2007) Effect of hepatic impairment on the pharmacokinetics, pharmacodynamics and tolerability of rivaroxaban-an oral, direct factor Xa inhibitor (abstract). J Thromb Haemost 5(Supplement 2):P-M-635","journal-title":"J Thromb Haemost"},{"issue":"Suppl 1","key":"967_CR93","first-page":"abstract 2024","volume":"33","author":"J Mendell","year":"2012","unstructured":"Mendell J, Ridout G, He L, Chen S (2012) An open-label, phase 1 study to evaluate the effects of hepatic impairment on edoxaban pharmacokinetics (abstract). Eur Heart J 33(Suppl 1):abstract 2024","journal-title":"Eur Heart J"},{"key":"967_CR94","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s40262-013-0034-0","volume":"52","author":"J Graff","year":"2013","unstructured":"Graff J, Harder S (2013) Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the hrombin inhibitor dabigatran etexilate in patients with hepatic impairment. Clin Pharmacokinet 52:243\u2013254","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"967_CR95","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2165\/11318170-000000000-00000","volume":"49","author":"J Stangier","year":"2010","unstructured":"Stangier J et al (2010) Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet 49(4):259\u2013268","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"967_CR96","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/j.1365-2125.2010.03753.x","volume":"70","author":"D Kubitza","year":"2010","unstructured":"Kubitza D et al (2010) Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol 70(5):703\u2013712","journal-title":"Br J Clin Pharmacol"},{"key":"967_CR97","doi-asserted-by":"crossref","unstructured":"Nessel C, Mahaffey K, Piccini J, et al. (2012) Incidence and outcomes of gastrointestinal hemorrhage in patients with atrial fibrillation treated with rivaroxaban or warfarin: results from the ROCKET AF trial. CHEST 142 (No. 4 Meeting Abstracts):84A\u201384A","DOI":"10.1378\/chest.1388403"},{"issue":"1","key":"967_CR98","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/jps.20536","volume":"95","author":"T Fujita","year":"2006","unstructured":"Fujita T et al (2006) Transport of drugs in the kidney by the human organic cation transporter, OCT2 and its genetic variants. J Pharm Sci 95(1):25\u201336","journal-title":"J Pharm Sci"},{"issue":"2","key":"967_CR99","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1124\/pr.110.003533","volume":"63","author":"Q Ma","year":"2011","unstructured":"Ma Q, Lu AYH (2011) Pharmacogenetics, pharmacogenomics, and individualized medicine. Pharmacol Rev 63(2):437\u2013459","journal-title":"Pharmacol Rev"},{"issue":"22","key":"967_CR100","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1056\/NEJMoa044503","volume":"352","author":"MJ Rieder","year":"2005","unstructured":"Rieder MJ et al (2005) Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 352(22):2285\u20132293","journal-title":"N Engl J Med"},{"issue":"4","key":"967_CR101","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/sj.tpj.6500313","volume":"5","author":"M Wadelius","year":"2005","unstructured":"Wadelius M et al (2005) Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J 5(4):262\u2013270","journal-title":"Pharmacogenomics J"},{"issue":"1","key":"967_CR102","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.clpt.2006.04.008","volume":"80","author":"UI Schwarz","year":"2006","unstructured":"Schwarz UI, Stein CM (2006) Genetic determinants of dose and clinical outcomes in patients receiving oral anticoagulants. Clin Pharmacol Ther 80(1):7\u201312","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"967_CR103","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1111\/j.1538-7836.2011.04437.x","volume":"9","author":"S Achterberg","year":"2011","unstructured":"Achterberg S et al (2011) Differential propensity for major hemorrhagic events in patients with different types of arterial disease. J Thromb Haemost 9(9):1724\u20131729","journal-title":"J Thromb Haemost"},{"issue":"4","key":"967_CR104","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1097\/HJR.0b013e3283361ce6","volume":"17","author":"S Achterberg","year":"2010","unstructured":"Achterberg S et al (2010) Patients with coronary, cerebrovascular or peripheral arterial obstructive disease differ in risk for new vascular events and mortality: the SMART study. Eur J Cardiovasc Prev & Rehabil 17(4):424\u2013430","journal-title":"Eur J Cardiovasc Prev & Rehabil"},{"issue":"6","key":"967_CR105","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1160\/TH09-11-0758","volume":"103","author":"J Ryn van","year":"2010","unstructured":"van Ryn J et al (2010) Dabigatran etexilate\u2014a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 103(6):1116\u20131127","journal-title":"Thromb Haemost"},{"issue":"14","key":"967_CR106","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1161\/CIRCULATIONAHA.111.029017","volume":"124","author":"ES Eerenberg","year":"2011","unstructured":"Eerenberg ES et al (2011) Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 124(14):1573\u20131579","journal-title":"Circulation"},{"issue":"2","key":"967_CR107","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1160\/TH12-03-0179","volume":"108","author":"R Marlu","year":"2012","unstructured":"Marlu R et al (2012) Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thromb Haemost 108(2):217\u2013224","journal-title":"Thromb Haemost"},{"issue":"2","key":"967_CR108","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1160\/TH11-09-0668","volume":"107","author":"T Fukuda","year":"2012","unstructured":"Fukuda T et al (2012) Reversal of anticoagulant effects of edoxaban, an oral, direct factor Xa inhibitor, with haemostatic agents. Thromb Haemost 107(2):253\u2013259","journal-title":"Thromb Haemost"},{"issue":"Suppl 1","key":"967_CR109","doi-asserted-by":"crossref","first-page":"S141","DOI":"10.1002\/ajh.23202","volume":"87","author":"S Kaatz","year":"2012","unstructured":"Kaatz S et al (2012) Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol 87(Suppl 1):S141\u2013S145","journal-title":"Am J Hematol"},{"key":"967_CR110","unstructured":"Boehringer Ingelheim Pharmaceuticals Inc. (2010) FDA Advisory Committee Dabigatran Briefing Document. Available from: www.fda.gov\/downloads\/advisorycommittee\/committeesmeetingmaterials\/drugs\/cardiovascularandrenaldrugsadvisorycommittee\/ucm226009.pdf Accessed 21 Jan 2013"},{"issue":"21","key":"967_CR111","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1161\/CIRCULATIONAHA.110.004747","volume":"123","author":"JW Eikelboom","year":"2011","unstructured":"Eikelboom JW et al (2011) Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 123(21):2363\u20132372","journal-title":"Circulation"},{"issue":"3","key":"967_CR112","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1007\/s11239-011-0561-1","volume":"31","author":"E Nutescu","year":"2011","unstructured":"Nutescu E, Chuatrisorn I, Hellenbart E (2011) Drug and dietary interactions of warfarin and novel oral anticoagulants: an update. J Thromb Thrombolysis 31(3):326\u2013343","journal-title":"J Thromb Thrombolysis"},{"issue":"2","key":"967_CR113","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1093\/eurheartj\/ehm575","volume":"29","author":"AGG Turpie","year":"2008","unstructured":"Turpie AGG (2008) New oral anticoagulants in atrial fibrillation. Eur Heart J 29(2):155\u2013165","journal-title":"Eur Heart J"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-013-0967-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11239-013-0967-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-013-0967-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T19:01:30Z","timestamp":1715713290000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11239-013-0967-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,17]]},"references-count":113,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["967"],"URL":"https:\/\/doi.org\/10.1007\/s11239-013-0967-z","relation":{},"ISSN":["0929-5305","1573-742X"],"issn-type":[{"value":"0929-5305","type":"print"},{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7,17]]}}}